Lv21
110 积分 2023-03-26 加入
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort
4天前
已完结
Myocardial Entropy and Risk Predictors in Hypertrophic Cardiomyopathy: An Analysis From the NHLBI HCM Registry
4天前
已完结
Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis
4天前
已完结
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
5天前
已完结
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
9天前
已完结
The ventilatory efficiency parameters outperform peak oxygen consumption in monitoring the therapy effects in patients with hypertrophic cardiomyopathy
10天前
已完结
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
11天前
已完结
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM
11天前
已完结
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
11天前
已完结
Real-World Candidacy to Mavacamten in a Contemporary Hypertrophic Obstructive Cardiomyopathy Population
11天前
已完结
皖公网安备34019202002308
